Clinical trial

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

NCT07516886

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

PROCEDURE · Unmapped registry intervention Radical Prostatectomy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2024-01-22

PhaseN/A

Conditions

Prostate Cancer (Post Prostatectomy)unresolved

Prostate Cancer (Adenocarcinoma)unresolved

Prostate Cancer (Diagnosis)unresolved

Prostate Specific Antigenunresolved

Radical Prostatectomyunresolved

Interventions

Radical ProstatectomyPROCEDURE

Sponsors & collaborators

Lithuanian University of Health Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07516886 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.